A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 24, 2012

Study Completion Date

May 24, 2012

Conditions
Hereditary Angioedema
Interventions
BIOLOGICAL

C1 inhibitor (human) [C1 INH]

Trial Locations (11)

11501

Winthrop University Hospital, Mineola

20902

Institute for Asthma and Allergy, Wheaton

30342

Family Allergy and Asthma Center, Atlanta

37909

East Tennessee Center for Clinical Research, Knoxville

45267

University of Cincinnati Medical Center, Cincinnati

75231

AARA Research Center, Dallas

77802

Bryan

85251

Allergy, Asthma and Immunology Associates, Scottsdale

97035

Baker Allergy, Asthma and Dermatology Research Center, Lake Oswego

97401

Allergy and Asthma Research Group, Eugene

99204

Marycliff Allergy Specialist, Spokane

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT00914966 - A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE | Biotech Hunter | Biotech Hunter